{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:04:09Z","timestamp":1785143049735,"version":"3.55.0"},"reference-count":33,"publisher":"American Chemical Society (ACS)","issue":"11","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["IRT1073"],"award-info":[{"award-number":["IRT1073"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","award":["XLYC2002115"],"award-info":[{"award-number":["XLYC2002115"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M762164"],"award-info":[{"award-number":["2024M762164"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Given the therapeutic potential of ROCK2 in pulmonary fibrosis (PF) and the significant efficacy of our previously identified lead compound 1, we initiated an optimization campaign focused on addressing physicochemical liabilities through disrupting molecular planarity. By implementing \u201csp3-rich\u201d and \u201cmagic methyl\u201d strategies, two series of ROCK2 inhibitors featuring 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine or imidazo[1,2-b]pyridazine scaffolds were developed. A dedicated evaluation discovered the optimal compound 39, which exhibited potent ROCK2 inhibition (IC50 = 0.0081 \u03bcM), enhanced kinetic solubility (77 \u03bcg\/mL in water), improved metabolic stability (t1\/2 = 5.0 h for p.o), favorable kinase selectivity, and an acceptable safety profile. Notably, 39 effectively suppressed TGF-\u03b21-induced fibroblast activation and migration, while significantly attenuating bleomycin-induced PF in vivo. Moreover, mechanistic studies revealed that the antifibrotic effects of 39 were mediated through inhibition of the TGF-\u03b2\/Smad and ROCK2\/STAT3 signaling pathways. Overall, these findings validate the proposed design strategy and deliver a novel candidate for ROCK2-targeted therapy in PF.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c00982","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:01:07Z","timestamp":1779714067000},"page":"13919-13940","source":"Crossref","is-referenced-by-count":0,"title":["Rational Optimization\nof Rho-Associated Coiled-Coil\nContaining Protein Kinase 2 Inhibitors via Disruption of Molecular\nPlanarity for Pulmonary Fibrosis"],"prefix":"10.1021","volume":"69","author":[{"given":"Zhi","family":"Cao","sequence":"first","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangfei","family":"Wei","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Yue","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youbao","family":"Cui","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Xu","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehui","family":"Tan","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-2405","authenticated-orcid":true,"given":"Xin","family":"Zhai","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"1","key":"2026072621082607000_cit1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s12967-025-06514-2","article-title":"Pulmonary fibrosis: from mechanisms to therapies","volume":"23","author":"Jiang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"4","key":"2026072621082607000_cit2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic\npulmonary fibrosis: state\nof the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"9","key":"2026072621082607000_cit3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/17512433.2024.2396121","article-title":"Emerging\npharmacological options\nin the treatment of idiopathic pulmonary fibrosis (IPF)","volume":"17","author":"Aribindi","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"2","key":"2026072621082607000_cit4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/crj.13466","article-title":"Idiopathic pulmonary fibrosis: Current\nand future treatment","volume":"16","author":"Glass","year":"2022","journal-title":"Clin. Respir. J."},{"issue":"9","key":"2026072621082607000_cit5","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive\nPulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical\nPractice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care\nMed."},{"issue":"6","key":"2026072621082607000_cit6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3390\/ph17060709","article-title":"Pirfenidone and Nintedanib\nin Pulmonary Fibrosis: Lights and Shadows","volume":"17","author":"Chianese","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"10","key":"2026072621082607000_cit7","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.3390\/biomedicines13102522","article-title":"Effects of\nAntifibrotic Therapy in Patients with Combined Pulmonary Fibrosis\nand Emphysema: A US-Based Cohort Study","volume":"13","author":"Shah","year":"2025","journal-title":"Biomedicines"},{"issue":"22","key":"2026072621082607000_cit8","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"FIBRONEER-IPF\nTrial Investigators. Nerandomilast in Patients with Idiopathic Pulmonary\nFibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"2026072621082607000_cit9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41584-025-01285-y","article-title":"Nerandomilast\nslows progression of pulmonary fibrosis","volume":"21","author":"Papatriantafyllou","year":"2025","journal-title":"Nat.\nRev. Rheumatol."},{"issue":"19","key":"2026072621082607000_cit10","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic Pulmonary\nFibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"2026072621082607000_cit11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-023-01950-0","article-title":"Current and\nFuture Treatment Landscape\nfor Idiopathic Pulmonary Fibrosis","volume":"83","author":"Bonella","year":"2023","journal-title":"Drugs"},{"issue":"7","key":"2026072621082607000_cit12","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1021\/acs.jmedchem.2c01753","article-title":"Application and Study of ROCK Inhibitors in Pulmonary\nFibrosis: Recent Developments and Future Perspectives","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026072621082607000_cit13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1124\/pr.114.009381","article-title":"The Rho\nkinases: critical mediators\nof multiple profibrotic processes and rational targets for new therapies\nfor pulmonary fibrosis","volume":"67","author":"Knipe","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"2026072621082607000_cit14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.108062","article-title":"Pharmacological\nprofile and therapeutic evaluation\nof ROC-101, a potent and selective ROCK inhibitor, in arterial hypertension\nand pulmonary fibrosis","volume":"223","author":"Mo","year":"2026","journal-title":"Pharmacol. Res."},{"issue":"13","key":"2026072621082607000_cit15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj9559","article-title":"Modeling mechanical\nactivation of macrophages during pulmonary fibrogenesis for targeted\nanti-fibrosis therapy","volume":"10","author":"Xu","year":"2024","journal-title":"Sci. Adv."},{"issue":"14","key":"2026072621082607000_cit16","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s40265-021-01593-z","article-title":"Belumosudil:\nFirst Approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"2026072621082607000_cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2022.103343","article-title":"Belumosudil with ROCK-2\ninhibition: chemical and therapeutic development\nto FDA approval for the treatment of chronic graft-versus-host disease","volume":"70","author":"Ali","year":"2022","journal-title":"Curr. Res. Transl. Med."},{"issue":"5","key":"2026072621082607000_cit18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/13543784.2025.2510667","article-title":"Role of ROCK2 inhibitors\nin the treatment of chronic\ngraft-versus-host disease","volume":"34","author":"Ngo","year":"2025","journal-title":"Expert Opin. Invest.\nDrugs"},{"issue":"1","key":"2026072621082607000_cit19","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1182\/blood-2025-4229","article-title":"TDI01 in the\ntreatment of moderate to severe chronic graft-versus-host\ndisease: Updated results from a multicenter, OPEN-label phase IB\/II\nstudy (An Update)","volume":"146","author":"Huang","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2026072621082607000_cit20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.drudis.2019.11.017","article-title":"ROCK-2-selective targeting\nand its therapeutic outcomes","volume":"25","author":"Sharma","year":"2020","journal-title":"Drug Discovery\nToday"},{"key":"2026072621082607000_cit21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106539","article-title":"Discovery of indoline-based\nderivatives as effective ROCK2 inhibitors for the potential new treatment\nof idiopathic pulmonary fibrosis","volume":"137","author":"Fu","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"20","key":"2026072621082607000_cit22","doi-asserted-by":"publisher","first-page":"21892","DOI":"10.1021\/acs.jmedchem.5c02233","article-title":"Identification of Novel\nImidazo[1,2-b]pyridazine Derivatives as Selective\nROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis","volume":"68","author":"Cao","year":"2025","journal-title":"J. Med. Chem."},{"issue":"20","key":"2026072621082607000_cit23","doi-asserted-by":"publisher","first-page":"20859","DOI":"10.1021\/acs.jmedchem.5c00287","article-title":"Challenges of Aufheben to Promote\nDruglikeness: Chemical Modification Strategies to Improve Aqueous\nSolubility and Permeability","volume":"68","author":"Ishikawa","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026072621082607000_cit24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1021\/jm101356p","article-title":"Improvement in aqueous solubility in small molecule\ndrug discovery programs by disruption of molecular planarity and symmetry","volume":"54","author":"Ishikawa","year":"2011","journal-title":"J. Med. Chem."},{"issue":"20","key":"2026072621082607000_cit25","doi-asserted-by":"publisher","first-page":"21615","DOI":"10.1021\/acs.jmedchem.5c01879","article-title":"Beyond Bioisosteres:\nImpact of Replacing a Benzene Ring with sp3-Rich Three-Dimensional\nSaturated Bridged Bicyclic Match Pairs on Biotransformation, Metabolic\nStability, and Other ADME Profiles","volume":"68","author":"Surendran","year":"2025","journal-title":"J. Med.\nChem."},{"issue":"22","key":"2026072621082607000_cit26","doi-asserted-by":"publisher","first-page":"13291","DOI":"10.1021\/acs.jmedchem.0c00829","article-title":"Opportunities\nfor Tapping into Three-Dimensional Chemical Space through a Quaternary\nCarbon","volume":"63","author":"Talele","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026072621082607000_cit27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/ph16081157","article-title":"The\nMagic Methyl and Its Tricks in\nDrug Discovery and Development","volume":"16","author":"Pinheiro","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"4","key":"2026072621082607000_cit28","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1021\/acs.jmedchem.4c02016","article-title":"Harnessing the Magic\nMethyl Effect: Discovery of CLPP-2068 as a Novel HsClpP Activator for the Treatment of Diffuse Large B-Cell Lymphoma","volume":"68","author":"Sun","year":"2025","journal-title":"J. Med. Chem."},{"issue":"22","key":"2026072621082607000_cit29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.164380","article-title":"Functional\nPdgfra fibroblast heterogeneity in normal and fibrotic mouse lung","volume":"8","author":"Trempus","year":"2023","journal-title":"JCI Insight"},{"issue":"7","key":"2026072621082607000_cit30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41573-025-01158-9","article-title":"Fibrosis: cross-organ\nbiology and\npathways to development of innovative drugs","volume":"24","author":"Rieder","year":"2025","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"10","key":"2026072621082607000_cit31","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1036","article-title":"Inhibition of ROCK\nameliorates pulmonary fibrosis by\nsuppressing M2 macrophage polarisation through phosphorylation of\nSTAT3","volume":"12","author":"Li","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"2","key":"2026072621082607000_cit32","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1074\/jbc.M403960200","article-title":"Role of Rho\/ROCK and p38 MAP kinase pathways in transforming\ngrowth factor-beta-mediated Smad-dependent growth inhibition of human\nbreast carcinoma cells in vivo","volume":"280","author":"Kamaraju","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"2026072621082607000_cit33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51889-3","article-title":"Activation of parkin by a molecular\nglue","volume":"15","author":"Sauve\u0301","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c00982","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/11\/13919\/66273007\/acs.jmedchem.6c00982.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/11\/13919\/66273007\/acs.jmedchem.6c00982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:17:32Z","timestamp":1785140252000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/11\/13919\/5201060\/Rational-Optimization-of-Rho-Associated-Coiled"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,5,25]]},"published-print":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c00982","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}